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Abstract The pituitary hormone prolactin (PRL) has
been implicated in tumourigenesis. Expression of PRL and
its receptor (PRLR) was reported in human breast epithe-
lium and breast cancer cells. It was suggested that PRL
may act as an autocrine/paracrine growth factor. Here, we
addressed the role of locally synthesised PRL in breast
cancer. We analysed the expression of PRL in human
breast cancer tumours using qPCR analysis and in situ
hybridization (ISH). PRL mRNA expression was very low
or undetectable in the majority of samples in three cDNA
arrays representing samples from 144 breast cancer
patients and in 13 of 14 breast cancer cell lines when
analysed by qPCR. In accordance, PRL expression did not
reach detectable levels in any of the 19 human breast
carcinomas or 5 cell lines, which were analysed using a
validated ISH protocol. Two T47D-derived breast cancer
cell lines were stably transfected with PRL-expressing
constructs. Conditioned medium from the T47D/PRL
clones promoted proliferation of lactogen-dependent Nb2
cells and control T47D cells. Surprisingly, the PRL-pro-
ducing clones themselves displayed a lower proliferation
rate as compared to the control cells. Their PRLR protein
level was reduced and the cells were no longer responsive
to exogenous recombinant PRL. Taken together, these data
strongly indicate that autocrine PRL signalling is unlikely
to be a general mechanism promoting tumour growth in
breast cancer patients.
Keywords Autocrine prolactin  Breast cancer 
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Introduction
The polypeptide hormone prolactin (PRL) is synthesised by
lactotrophs of the anterior pituitary and acts as a classical
endocrine hormone. PRL is important for proliferation and
differentiation of the breast epithelium as well as for
stimulation of lactation after delivery [1]. PRL mediates its
effects through the PRL receptor (PRLR). It binds via site 1
to one receptor chain forming a 1:1 ligand–receptor com-
plex. Subsequent binding to a second identical receptor
molecule via binding site 2 results in the active 1:2 ligand–
receptor complex. Upon dimerization, PRLR and associ-
ated JAKs become phosphorylated and activate multiple
signalling pathways including STAT5, STAT3, ERK1/2
and AKT. PRL binding also induces PRLR ubiquitination,
internalisation and degradation [2].
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A number of studies have pointed towards a role of PRL
in breast cancer development. Increased plasma concen-
tration of PRL observed in breast cancer patients positively
correlated with poor prognosis and the occurrence of
metastatic breast cancer [3]. A growth-promoting effect of
PRL on human breast cancer cells in vitro has been dem-
onstrated by several laboratories including ours [4–6]. In
addition, PRL was shown to play a role in development of
murine mammary tumours [7–9]. It has been reported that
in humans PRL can be produced at extra pituitary sites [10,
11]. Although at markedly lower levels compared to pitu-
itary, PRL mRNA expression was clearly demonstrated in
placental decidualized endometrium specimens by Geller-
sen et al. [12]. Moreover, PRL mRNA was also detected in
normal breast epithelium and breast cancer tissues [13–18]
and since PRLR was also found to be expressed in the
breast gland and breast cancer cells, it was hypothesised
that PRL can promote breast cancer progression in an
autocrine/paracrine manner.
To mimic the proposed autocrine/paracrine loop in
human, transgenic murine models with tissue-specific PRL
expression were used. Local overexpression of PRL was
found to promote breast cancer development in virgin
transgenic animals [8, 9, 19]. In contrast, no carcinomas
were found in PRL transgenic mice with differentiated
mammary glands, where PRL expression was controlled by
the milk whey acidic protein promotor [20]. Overexpres-
sion of PRL was also found to stimulate cell growth of the
transfected human breast cancer cell lines, MCF-7 and
MDA-MB435 [21, 22]. However, to date, it still remains
unclear whether locally produced PRL contributes to
human breast cancer progression.
In the present study, expression of PRL in breast cancer
tissues and breast cancer cell lines as well as the potential
role of local PRL in stimulation of cancer cell proliferation
has been addressed. We show based on the analysis of
mRNA expression in human breast cancer samples and
in vitro studies with transfected breast cancer cell lines that
locally synthesised PRL is unlikely to be a general mech-
anism promoting breast cancer progression.
Materials and methods
Breast cancer cell cultures and hormones
Human breast cancer cell lines MDA-MB361, AU565,
BT20, BT474, BT549, MDA-MB157, MCF-7, MDA-
MB175 VII, MDA-MB231, MDA-MB468, SK-BR-3, ZR-
75-1 and T47D were purchased from ATCC (Manassas,
VA), the T47D Tet-On cell line was from Clontech
(Mountain View, CA), MFM 233 was purchased from
ECACC (Salisbury, UK). Cells were routinely cultured in
DMEM medium supplemented with 10 % FCS, 2 mM
glutamax, 4.5 g/l glucose (Invitrogen, San Diego, CA) and
100U penicillin/streptomycin (Invitrogen, San Diego, CA).
In case of T47D, cell culture medium was supplemented with
0.01 U/ml human insulin (Novo Nordisk A/S, Denmark).
For T47D Tet-On derived cells 10 % FCS was replaced with
10 % Tet System Approved FCS (Clontech, Mountain View,
CA). In order to study the effects of ectopic and exogenous
PRL, cells were cultured in phenol red-free DMEM sup-
plemented with 10 % charcoal/dextran stripped FCS (Hy-
Clone, Logan, UT), 2 mM glutamax, 4.5 g/l glucose, 100 U
penicillin and streptomycin (Invitrogen, San Diego, CA)
(referred as 10 % CSS medium). All cells were propagated in
5 % CO2 humidified atmosphere at 37 C. Human recom-
binant PRL (rPRL) was expressed in Escherichia coli and
purified as previously described [23]. 17-estradiol (E2) was
purchased from Sigma-Aldrich (St.Louis, MO).
Detection of PRL mRNA in breast cancer tissue
and breast cancer cell lines by qPCR analysis
Breast Cancer cDNA Arrays I, II and IV were obtained
from Origene (Origene cat# BCRT301, BCRT302 and
BCRT303); according to supplier infiormation, each array
contained cDNA samples synthesised from high quality
total RNAs of pathologist-verified tissues, normalised and
validated with ACTB (b-actin) in two sequential qPCR
analyses; arrays were provided with clinical information
and quality control data, but absolute amount of cDNA/
well was not disclosed. BCRT301 contained 48 samples
covering 7 stage 0, 10 stage I, 13 stage IIA, 7 stage IIB, 8
stage IIIA and 3 stage IIIC breast cancers; BCRT302—48
samples covering 5 stage 0, 11 Stage I, 8 IIA, 6 IIB, 8 IIIA,
2 IIIB, 4 IIIC, 4 IV breast cancers; BCRT304—48 samples
covering 4 stage 0, 2 stage I, 15 stage IIA, 9 stage IIB, 7
stage IIIA, 4 stage IIIB, 6 stage IIIC and 1 stage IV breast
cancers. Two BCRT302 plates were used with undiluted
samples for qPCR in a PRL-specific assay; another plate
was divided in 4 equal aliquots and used for control qPCR
analysis for PRLR (PRL receptor), PLAU, PLAUR
(encoding uPA receptor) and ACTB. From each of
BCRT301 and 304, two undiluted plates were used for PRL
qPCR and one undiluted plate for ACTB. In order to
increase the amounts of PRL and control cDNA in the
Origene plates, one plate from BCRT301 was used for
multiplex pre-amplification. Pre-amplification was per-
formed using the TaqMan PreAmp Kit PN4384267
(Applied Biosystems) with a combination of the ABI
assays for PRL and ACTB; cDNA samples were dissolved
in 50 ll assay mix and split into two equal aliquots which
were both subjected to 14 cycles amplification as recom-
mended by the kit manual, except that the final amplified
samples were diluted only 5 times instead of 20 times.
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Breast cancer cell lines grown under standard conditions
were used for isolation of total RNA, using TRIZOL.
cDNA was prepared from 1 lg of total RNA from each of
the preparations using random primers and Superscript II
Reverse Transcription reagents (Invitrogen A/S San Diego,
CA) according to the manufacturer’s instructions. Placental
RNA (Clontech cat# 636527) was used for cDNA synthesis
as described for the cell line RNAs. For qPCR we used a
cDNA amount corresponding to 40 ng total RNA pr.
reaction. Primers and FAM-labelled-probes for PRL and
control genes were ordered as Assays-on-Demand from
Applied Biosystems. Assay order numbers for these genes
were: PRL Hs00168730_m1 (this assay is recommended
by ABI to give best coverage of all PRL splice variants);
PRLR Hs00168739_m1; PLAU Hs01547050_m1;
PLAUR-1 Hs00182181_m1 and ACTB Hs99999903_m1.
Quantitative PCR (50 cycles) was performed on each of
the cDNA samples with TaqMan PCR core reagents
(Applied Biosystems), using the ABI PRISM 7900HT
Sequence Detection System. Data were analysed using ABI
Prism SDS 2.2 software (Applied Biosystems); expression
levels for each mRNA were estimated from the Ct values;
for the breast cancer samples of BCRT302, Ct values for
control genes have been corrected so as to reflect the values
of undiluted samples. According to Applied Biosystems, Ct
values of *40 reflect the limit of detection, and values
close to or above this limit are usually not reliable (referred
as ‘undetermined’ further in the text).
Clinical tissue samples and cell lines for histology
Breast cancer samples
Formalin-fixed and paraffin-embedded (FFPE) human
breast cancer carcinoma tissue samples from 19 patients
were obtained from the biobank at Nordsjaellands Hospital,
Hilleroed. The age of the patients was in the range
42–86 years with a median of 57 years. 15 patients had
ductal carcinomas and four had lobular carcinomas. These
carcinomas were classified as malignancy grade I (n = 1),
II (n = 6) and III (n = 8). The grade was not reported for
four of the tumours. 11 patients had lymph node metasta-
ses. Most of the tumours (14/19) expressed the estrogen
receptor, and a subset of these (11/14) also expressed the
progesterone receptor (Supplementary Table 2S).
Positive control tissues and cell lines
Human pituitary gland (FFPE) was obtained as tissue
blocks (cat. no. 24070250), and as cut sections from
Cambridge Bioscience Ltd., Cambridge, UK and from
Pantomics, respectively. Human placenta (FFPE) was
collected at Odense University and kindly provided by Dr.
Tornehave. Human breast cancer-derived cell lines (MDA-
MB361, AU565, BT20, BT474, BT549, MDA-MB157,
MCF-7, MDA-MB175 VII, MDA-MB231, MDA-MB468,
SK-BR-3, ZR-75-1, MFM223), T47D/PRL clones and
control T47D cell lines (5–10x106 cells of each) were fixed
in paraformaldehyde and embedded in small agar cylinders
for processing and subsequent paraffin-embedding. All
breast cancer and control tissue samples were collected
with informed concent. Moreover, collection of tissues as
well as conduction of the present study was approved by
the local ethical committees.
Generation of S35-labelled PRL cRNA probes
A 507 bp PRL cDNA fragment (nucleotides 210–716
according to Genebank # BC088370) was amplified from
the pET32-PRL plasmid [23] by PCR using forward and
reverse primers 50 cccactacatccataacctctc and 50 ggatgat
tcggcacttcag, respectively. The PCR fragment was cloned
into PCR-Script Amp SK (?) cloning vector. The PRL
sequence was verified (service provided by MWG-Biotech,
Germany).
As a control for the specificity of the hybridization of the
PRL cRNA probe, two additional PRL probes were designed.
They were shorter (196 and 222 bp) and represented two non-
overlapping regions of the PRL cDNA corresponding to
nucleotides 210–405 and 495–716, respectively. The fol-
lowing forward and reverse primer sets were used to generate
the two DNA fragments: 50cccactacatccataacctctc ? 50cag-
gatcgcaatatgctgac, and 50agcaaaccaaacggcttc ? 50ggatgattc
ggcacttcag, respectively.
To validate the suitability of the breast cancer samples
for the ISH application, hybridization with a cRNA probe
for the cancer marker gene PLAU-1, encoding urokinase
plasminogen activator (uPA), was used. This probe repre-
sents a 513 bp fragment of the open reading frame of the
PLAU gene (corresponding to bp 691–1,024 in EMBO
database AQC #KO3226). It has previously been used to
detect the PLAU gene expression in human breast cancer
by ISH [24]. 35S-UTP radiolabelled sense and antisense
cRNA probes were transcribed from linearized plasmids
using T3 or T7 polymerases.
In situ hybridization (ISH)
Paraffin-embedded tissue sections (4 lm) were deparaf-
finised, rehydrated and pre-treated with proteinase K (5 lg/
ml) at 37 C for 5 min followed by post-fixation in 4 %
paraformaldehyde for 5 min. After acetylation and dehy-
dration, denatured 35S-UTP labelled anti-sense or sense
cRNA probes (500,000 cpm per ll hybridization solution:
19 SALTS with 50 % formamide, 12.5 % dextran sul-
phate, 1 lg/ml tRNA and 10 mM DTT) were added. The
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tissue sections were incubated overnight with a probe at
47 C in humidified atmosphere and hereafter washed in 1x
SALTS with 50 % formamide and 10 mM DTT two times
for 1 h at 62 and 67 C, respectively. The sections were
treated with RNase A (20 lg/ml) for 30 min at 37 C to
further remove excess probe followed by additional
washing for 30 min in 0.19 SSC with 1 mM DTT at room
temperature (RT). Sections were dehydrated, air dried and
dipped in auto-radiographic emulsion (Ilford K5). Slides
with T47D/PRL clones, control cell lines and anterior
pituitary tissue were developed after 1–2 weeks of expo-
sure, whereas slides with placenta, breast carcinoma tissue
and breast cancer cell lines were developed after
6–8 weeks of exposure. After development, slides were
counterstained with Mayer’s haematoxylin and eosin and
then examined and photographed under both dark- and
bright-field illumination. Positive hybridization with anti-
sense probes was defined as clusters of silver grains
observed over cells at densities higher than in sections
hybridized with sense probe.
PRL expression vectors
Full-length human PRL cDNA was amplified using an
expression plasmid previously described [23] as template
with the following set of primers: 50-ggttgctagctcacgaa-
catgaacatcaaagga and 50-gtttggatccttagcagttgttgttgtggatgatt
harbouring NheI and BamHI sites, respectively (underlined)
to facilitate cloning to the corresponding sites of the
pIRESneo2 expression vector (Clontech, Mountain View,
CA). For cloning into the pTRE2hyg vector (Invitrogen, San
Diego, CA), PRL cDNA was amplified using the following
set of primers: 50-ggttggatcctcacgaacatgaacatcaaagga and 50-
gtttgtcgacttagcagttgttgttgtggatgatt harbouring BamHI and
SalI sites, respectively (underlined) to facilitate cloning to
the corresponding sites of the vector. All constructs have
been sequences. Transfection of T47D and T47D Tet-On
cells was performed using Nucleofector (Amaxa Biosys-
tems). T47D cells were transfected with 2 lg of pIRESneo2-
hPRL (referred as T47D/pIRES-PRL); T47D Tet-On cells
were transfected with pTRE2hyg-hPRL (referred as T47D/
pTRE-PRL). Stable transfectants were selected using ge-
neticin (500 lg/ml) and hygromycin (200 lg/ml) for PRL-
transfected T47D and T47D Tet-On, respectively. Parental
T47D and mock (empty vector) transfected T47D Tet-On
drug resistant pool were used as controls.
Western blotting
Western blot analysis was carried out as previously
described [25]. For intracellular signalling studies, cells
were rinsed with ice-cold PBS and snap frozen in liquid
nitrogen prior to lysis in RIPA buffer. The following
primary antibodies were used: anti-PRL rabbit polyclonal
serum from AbCam (Cambridge, UK), anti-PRLR (clone
1A2B1) from Zymed (Invitrogen, San Diego, CA), anti-b-
actin from AbCam (Cambridge, UK), anti-ERK1/2, anti-
Cyclin D1 and anti-Bcl-2 from Cell Signalling Technolo-
gies (Danvers, MA), and anti-pERK1/2 (‘anti-active
MAPK’) from Promega (Fitchburg, WI). Secondary HRP-
conjugated goat anti-mouse and swine anti-rabbit anti-
bodies were purchased from Dako (Glostrup, Denmark).
Image acquisition was performed using an LAS-3000
image reader (Fujifilm, Japan); the signal intensity was
quantified using an Image Gauge V4 software.
Analysis of cell proliferation
Cell proliferation was estimated by measuring DNA syn-
thesis using 3H-thymidine incorporation as previously
described [6]. In brief, cells were incubated for 4 hrs with
0.5 lCi 3H-thymidine with a specific activity 59.0 Ci/
mmol (GE Healthcare, UK), detached by trypsin and har-
vested using a 96-well cell harvester (TOMTEC, Hamden
CT). 3H-thymidine incorporation was measured by liquid
scintillation counting using a TopCount NXT (Perkin
Elmer, Wellesley MA). Each treatment was performed in
four to six replicates.
Detection of secreted PRL
T47D and T47D/PRL cells were grown until 50–80 %
confluence in 10 % FCS supplemented medium. To
remove bovine PRL from the FCS medium, cells were
washed twice in DMEM prior to 24 h of starvation in
serum-free DMEM medium. Conditioned medium was
collected (on ice) and the PRL content was analysed as
described below. Cells were trypsinised and counted using
a Nucleocounter (Chemometec).
The level of secreted PRL protein was measured using
an ELISA kit (Duoset Human Prolactin, R&D Systems,
Abingdon, UK) according to the manufacturer’s protocol.
The PRL standards (15.625–1,000 pg/ml) and the condi-
tioned medium (undiluted and 59, 109, 509 or 1009
diluted) were analysed in duplicates and triplicates,
respectively.
The level of biologically active PRL in the conditioned
medium was measured using an Nb2 proliferation assay.
The Nb2 rat T cell lymphoma cell line (purchased from
ATCC) was routinely cultured in RPMI 1640 medium
supplemented with 10 % FCS, 10 % horse serum, 1 %
non-essential amino acids, 2 mM glutamax, 100 lM
2-mercaptoethanol, 100 U penicillin and streptomycin
(Invitrogen, San Diego, CA). To remove PRL from the
medium and to arrest growth of the cells prior to the assay,
Nb2 cells were starved for 24 h in phenol red-free RPMI
34 Breast Cancer Res Treat (2013) 142:31–44
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1640 medium supplemented with 1 % horse serum, 1 %
non-essential amino acids, 2 mM glutamax, 100 lM
2-mercaptoethanol, 100 U penicillin and streptomycin
(Invitrogen, San Diego, CA) (starvation medium). 2 9 104
cells were seeded per well in a 96-well multi-dish. Human
rPRL standards (Sigma, conc. 0.01–1,000 pM) and condi-
tioned medium (undiluted and 109 or 1009 diluted in
starvation medium) were added in duplicates and cells
were propagated for three days at 37 C in a 5 % CO2
humidified incubator. Nb2 cell proliferation was indirectly
estimated by measuring the metabolic activity of viable
Nb2 cells using AlamarBlue (BioSource, Nivelles, Bel-
gium). Cells were incubated with 0.04 % AlamarBlue for
4 h (37 C, 5 % CO2). As a negative control, AlamarBlue
was added to medium without cells. Absorbance of Ala-
marBlue was measured in a Wallac Victor plate reader
using a fluorescent excitation wavelength of 544 nm and
fluorescence emission at 590 nm. The level of biologically
active PRL in the conditioned medium was calculated
based on the human rPRL standard curve after correction
for background values of negative control samples.
Co-culture of T47D and T47D/PRL clones
T47D Tet-On cells were seeded at a density of 6 9 104
cells/well in a 24-well Falcon companion dish (BD Bio-
Coat, BD Biosciences, San Diego, CA) in 10 % CSS
medium. After one day, 0.4 lm cell culture inserts (BD
Falcon, BD Biosciences, San Diego, CA) were placed on
top of each well and cells were seeded in the inserts with a
density of approximately 80 % (7 9 104 T47D Tet-On
cells or 9 9 104 T47D/pTRE-PRL Cl.4 cells). Cells were
cultured for three days in 10 % CSS medium without
removal of the medium to allow accumulation of PRL
secreted by the T47D/PRL clones. The inserts were dis-
carded and the PRL concentration in the medium was
measured by ELISA as described above. Proliferation of
cells was measured as described above.
Cell cycle analysis
Cells were cultured for three days in 10 % FCS medium;
each treatment was performed in triplicates. To include all
cells, attached cells were harvested by EDTA/trypsin
treatment and loose/suspension cells were collected from
the medium. Cells were spun down, resuspended in PBS
with 1 % FCS and passed through a 45 lm cell strainer to
obtain a single cell suspension. DNA content was analysed
by staining of permeabilised cells with propidium iodide.
In brief, 1 9 105 cells were rinsed with ice-cold PBS with
1 % FCS, fixed in ice-cold 70 % EtOH over night at
-20 C and treated with a mixture of 25 lg/ml RNase and
50 lg/ml propidum iodide (BD Pharmingen, San Diego,
CA) for at least 20 min at RT (kept dark). The cells were
analysed using a BD FACSArrayTM flow cytometer. The
cell cycle phase distribution was analysed using ModFit
LTTM (Verity Software House) after exclusion of debris
and doublets by manual gating.
Flow cytometry analysis of PRLR expression
Cells were detached using Versene solution and counted
using a Nucleocounter. 1 9 105 cells were transferred to a
U-bottom 96-well dish (Falcon, BD). Unspecific binding
was blocked using PBS with 2 % FCS (30 min at 37 C).
Cells were stained with 1 lg/ml anti-PRLR mAb (Clone
250448; R&D Systems) for 45 min at 37 C or with mouse
IgG1 isotype control (BD Pharmingen, San Diego, CA).
Cells were rinsed once with cold PBS/0.5 % BSA and
incubated with APC-conjugated anti-mouse IgG (Jackson
ImmunoResearch, Suffolk, UK) for 30 min at 4 C. Cells
were rinsed four times with cold PBS/0.5 %BSA and
analysed by flow cytometry using BD FACSArray (BD
Bioscience, San Diego CA).
Results
PRL mRNA expression in human breast carcinomas
and cell lines analysed by qPCR
First, we validated the PRL and control qPCR assays on
placental RNA. Under the conditions used, placenta showed
a deltaCt value for PRL versus b-actin (ACTB) of 3.2
(Table 1), i.e. the PRL mRNA level was 9.2-fold lower than
the ACTB mRNA level. Next, we examined 3 different
commercial breast cancer cDNA arrays containing totally
144 samples (Table 1). Again, we used the deltaCt value for
PRL vs ACTB as measure for PRL levels. We showed that
ACTB Ct levels varied slightly between individual samples
and markedly among the three arrays, demonstrating that
Array I had a higher ACTB content followed by Array II and
Array IV. PRL Ct values were generally high and many
samples did not give rise to a Ct value at all (Ct [ 41), i.e.
PRL was undetectable. The number of samples with unde-
tected PRL mRNA was 16, 27 and 32 on arrays I, II and IV,
respectively, reflecting the influence of cDNA template
amount on the sensitivity of qPCR analysis. Using a PRL Ct
value of[41 for these 75 samples, we could calculate del-
taCT values vs ACTB demonstrating PRL levels that were at
least 20.000-fold lower than in placenta in 28 of the samples
and at least 100–2,000-fold lower than placenta in 47 sam-
ples. In the samples giving a PRL Ct value only one (sam-
ple#34 on Array IV) had a value, which is close to the PRL
level found in placenta, indicating a relatively high PRL
level. 8 samples had medium PRL mRNA levels (8–32-fold
Breast Cancer Res Treat (2013) 142:31–44 35
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lower than placenta). 42 samples had low to very low PRL
mRNA level (100–2,000-fold lower than placenta) and 18
samples had values at the border of the detection limit
(20,000-fold lower than placenta). Supplementary Table 1S
shows the individual Ct and deltaCt values for all samples.
The sensitivity of the assay was improved by pream-
plification of PRL and ACTB with 14 PCR cycles prior to
running qPCR analysis (Supplementary Table 1S (A). The
results confirmed that many samples indeed exhibited
insignificant PRL signals. Control qPCR to detect the
cancer marker genes PLAU and PLAUR with Array II
showed that the cDNA quality and quantity was sufficient
for detection of the analysed genes. In addition, all ana-
lysed samples showed PRLR mRNA expression.
Furthermore, qPCR analysis was used to examine PRL
mRNA expression in 14 human breast cancer cell lines
(Table 2). The PRL mRNA level in T47D cells was about
20,000-fold lower than that in placenta and corresponded
to the expression level in 18 breast cancer tissue samples
with values near the detection limit. In all the other tested
breast cancer cell lines, PRL values were extremely low or
undetectable. In contrast, all tested cell lines showed high
to medium levels of PRLR mRNA, while the cancer
markers PLAU and PLAUR (encoding uPA receptor) dis-
played mRNA medium to low mRNA levels. In summary,
we conclude that a majority of breast cancer samples as
well as breast cancer cell lines have very low to negligible
levels of PRL mRNA, and that only in very rare instances
higher PRL mRNA levels can be found.
Analysis of PRL mRNA expression in human breast
carcinomas and cell lines at the cellular level by ISH
As a positive control, the ISH technique for PRL detection
was first tested using the pituitary gland and placenta, both
tissues well known to express PRL. ISH readily detected
PRL mRNA expression in tissue sections of pituitary gland
(Fig. 1a, b, a’,b’) and after prolonged exposure time
(8 weeks compared to 2 weeks for pituitary gland) PRL
mRNA expression was also easily detected in tissue sec-
tions of human placenta (Fig. 1d, e, d’, e’), confirming
results by Gellersen et al. [12]. Whereas PRL is expressed
at high levels in pituitary gland for endocrine purposes,
PRL expression in placenta rather has autocrine/paracrine
function and is thus a relevant positive control for the
reported autocrine/paracrine expression of PRL in human
breast cancers.
The PRL sense probe (used as a negative control for
unspecific binding and binding of probes to genomic DNA)
did not generate detectable hybridization signals on any of
the sections tested, confirming specific hybridization of the
probes under the conditions used (Fig. 1c, c’, f, f’). As an
additional control for specificity of the hybridization of the
long PRL cRNA probe (507 bp), two shorter probes (196
and 222 bp) representing non-overlapping regions of the
PRL gene demonstrated the same hybridization signals of
similar intensity as the longer probe on pituitary gland
(Supplementary Fig. 1s) thus validating the specificity of
the ISH procedure employed in the present study to detect
PRL mRNA transcripts.
Moreover, to verify that the tissue samples used in the
present study were suitable for the ISH application, ISH
was performed with a 35S-labelled cRNA probe repre-
senting the cancer marker gene PLAU-1 (encoding uPA
protein). Expression of this gene in human breast cancer
has previously been demonstrated by ISH [24]. Accord-
ingly, we obtained a positive-ISH signal with the PLAU-1
probe in all 19 samples of human breast carcinoma inclu-
ded in this study (Supplementary Fig. 2s). The origin of
these samples is described in the Materials and Methods
Table 1 PRL qPCR analysis of Breast Cancer samples and placenta
Placenta PRL PRL vs ACTB ACTB
Ct deltaCt Ct
27.2 3.2 24
No of
undetermined
samples
Ct
average
Ct range
(PRL nd)
deltaCt
average
deltaCt ra
nge (PRL nd)
No of
undetermined
samples
Ct average all
(PRL nd)
Ct range all
(PRL nd)
Breast cancer
cDNA array I
16/48 39 ± 1.2 36.3–41.3
([41)
13.4 ± 1.9 6.3–16.2
([15–16.7)
0 25.1 ± 1.2
(25 ± 0,6)
23.7–32 (24.3–26)
Breast cancer
cDNA array II
27/48 39 ± 1.1 36.8–40.9
([41)
12 ± 1.5 7.3–14.1
([12.1–15)
0 27.4 ± 0.7
(27.4 ± 0.7)
26.0–29.5 (26-28.9)
Breast cancer
cDNA array
IV
32/48 39 ± 1.8 35.3–41.4
([41)
9 ± 2.7 3.8–13.6
([7.1–14.7)
0 28.6 ± 1.6
(28.3 ± 1.5)
26.5–33.9(26.3–33.9)
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section and the clinicopathological characteristics of the
patients are listed in Supplementary Table 2S.
We then analysed PRL mRNA expression in these 19
human breast cancer samples. In none of them we were
able to detect expression of PRL mRNA by the ISH
technique (Fig. 1g, h, g’, h’ and data not shown). Impor-
tantly, these data show that PRL mRNA expression was not
induced in a minor subset of human breast cancer cells
Table 2 qPCR analysis of breast cancer cell lines
PRL PRLR PLAU-1 PLAUR-1 ACTB
T47D 36.1 22.0 35.3 32.4 21.3
MDA-MB361 39.6 23.2 34.0 35.0 20.3
AU565 38.5 26.4 40.1 28.3 20.5
BT20 Undetermined 30.8 35.5 27.0 20.3
BT474 Undetermined 24.9 35.7 37.4 20.9
BT549 Undetermined 29.0 25.6 25.1 19.7
MCF-7 Undetermined 25.9 35.3 30.2 21.4
MDA-MB157 34.4 28.1 30.5 28.3 20.7
MDA-MB175 VII 41.0 27.1 34.5 30.9 22.1
MDA-MB231 Undetermined 31.0 26.2 27.3 21.5
MDA-MB468 39.5 28.3 31.8 26.4 20.8
SK-BR-3 Undetermined 27.0 31.5 30.3 21.6
ZR-75-1 37.1 26.5 37.2 28.5 20.2
MFM 223 40.9 25.8 34.6 33.2 21.6
Ct range 34.4-undetermined 22–31 25.6–40.1 25.1–37.4 19.7–22.1
Fig. 1 Analysis of PRL mRNA expression in the pituitary gland,
placenta, breast carcinoma and adjacent normal breast tissue by ISH.
Bright field and dark field pictures are shown. A 507 bp PRL cRNA
antisense probe (AS PRL) was hybridized onto sections of paraffin-
embedded anterior pituitary, placental decidua, invasive ductal
carcinoma of the breast and adjacent normal breast epithelium tissues
as indicated. Additional adjacent sections were hybridized with PRL
sense probe (S PRL) as a negative control. Signal is visualised under
dark field as white grains. Bright field represents the haematoxylin
and eosin stained sections after hybridization with PRL antisense
probe. Under bright field ISH signal is visualised as black grains.
Sections of anterior pituitary tissue were developed after 2 weeks of
exposure whereas the other tissue sections were developed after
8 weeks of exposure. Representative pictures are shown at both low
and high magnification (left and right panel, respectively). Scale
bars = 100 lm
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within the same tumour, which might not have been
detected by the qPCR technique. Adjacent normal breast
epithelium, present in some of the cancer tissue samples,
likewise expressed PRL mRNA at levels below the
detection limit of the assay (Fig. 1j, k, j’, k’ and data not
shown). Supporting these data, PRL mRNA expression was
also not observed when ISH was performed on human
breast cancer tissue microarray (TMA) slides from com-
mercial sources representing tumours from 84 breast can-
cer patients (data not shown).
Finally, a small panel of human breast cancer cell lines
was analysed for PRL mRNA expression by the ISH
technique. None of the tested cells (T47D, AU565, MDA-
MB157, BT483, and ZR-75-1) expressed detectable levels
of PRL mRNA (Fig. 2a and data not shown).
Establishment of T47D clones secreting PRL
In order to mechanistically address a putative tumour
growth-promoting role of the autocrine PRL, which was
suggested in a number of published studies, we ectopically
expressed PRL in human breast tumour cells and studied
their phenotype. As we previously detected a high PRLR
expression level in T47D cells [Table 2; 25] and the cells
demonstrated a significant proliferative response to exoge-
nous recombinant PRL [6], this cell line was chosen for the
study. Expression of endogenous PRL in these cells was
very low/negligible on the RNA level (Fig. 2a; Table 2) and
not detectable on the protein level (Fig. 2b). Therefore, we
stably transfected T47D cells as well as their established
subclone, T47D Tet-On, with either pIRESneo2-hPRL
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Fig. 2 Establishment of T47D/PRL clones with high levels of
ectopic PRL expression a ISH analysis of PRL mRNA expression
in wild type and PRL-transfected cell lines. Bright field (BF) and dark
field (DF) pictures are shown. Sections of paraffin-embedded cells
were hybridized with an antisense cRNA probe (507 bp) comple-
mentary to the PRL mRNA (AS PRL). Signal is visualised under DF
as white grains. BF represents the haematoxylin and eosin stained
sections after hybridization with AS PRL probe to show morphology
of the cells. Under BF ISH signal is visualised as black grains. Lack
of detectable hybridization signal with sense probe (S PRL) indicates
specificity of signals obtained with the PRL AS probe. Sections were
developed after 2 weeks of exposure. Scale bars = 100 lm. b Ana-
lysis of the PRL protein expression. Cells were grown to 70–80 %
confluence in 10 % FCS medium and then starved for 24 h in serum-
free DMEM medium. 20 lg of cellular protein extracts were analysed
by Western blotting using a PRL-specific antibody (top panel); b-
actin was used as protein loading control (lower panel). Supernatants
were analysed for secreted and active PRL using ELISA and Nb2
proliferation, respectively. The PRL level is stated as nmoles/1 mio
cells/24 h. b.d. below detection limit. c Transwell co-culture of T47D
and T47D/PRL cells. T47D Tet-On cells were seeded in 24-well
multi-dishes in 10 % CSS medium. After 24 h of plating, inserts with
either T47D Tet-On or T47D/pTRE-PRL Cl.4 cells were placed on
top of T47D Tet-On cells. After three days of culture, inserts were
discarded. The PRL level in the medium was analysed by ELISA,
while proliferation of T47D Tet-On cells was measured using 3H-
thymidine incorporation. Mean ± SD of four independent wells are
shown
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vector for constitutive expression of PRL or pTRE2hyg2-
hPRL for Tet-inducible expression of PRL, respectively.
Two T47D/pIRES-PRL clones (1:B3 and 2:C10) and one
T47D/pTRE-PRL clone (Cl.4) were selected for the ana-
lysis. Transcription of PRL was detected by ISH (Fig. 2a).
Expression of the PRL protein was confirmed by Western
blotting (Fig. 2b). The majority of the PRL protein expres-
sed by transfected T47D cells appeared to have the same
electrophoretic mobility as the recombinant PRL produced
in E.coli, i.e. did not seem to be glycosylated. However, a
band of unknown identity with a lower electrophoretic
mobility can also be detected in Cl.4. Secretion of PRL was
analysed in serum-free conditioned media for the total and
biologically active protein using ELISA and an Nb2 cell
proliferation assay, respectively (Fig. 2b). The latter assay is
widely used to quantify biologically active PRL capable of
inducing proliferation of lactotroph-dependent Nb2 cells
[21, 26]. We found a good correlation between the expres-
sion levels of PRL mRNA, total PRL protein, secreted PRL
and bioactive PRL in the analysed cells. Cl.4 was found to
express a significantly higher level of PRL than 1:B3 and
2:C10 clones. Expression of PRL in the two control T47D
cell lines was undetectable by any of the above mentioned
assays. However, a very low PRL transcription level was
detected in T47D cells by qPCR (see previous section;
Table 2). If these cells were capable of secreting any PRL
protein, its amount was below detection limits of the ELISA
and Nb2 assays, which was estimated to correspond to
47 pg/106 cells/24 h and 69 pg/106 cells/24 h, respectively.
Noteworthy, despite the T47D Tet-On cell line is designed
to be an inducible gene expression system, where the gene of
interest is expressed only in the presence of doxycycline,
PRL was constitutively produced by the T47D/pTRE-PRL
clone Cl.4 and no major induction of PRL expression was
observed by addition of doxycycline (data not shown).
Therefore, in this study the T47D/pTRE-PRL Cl.4 was used
as a constitutive PRL expressing cell line without doxycy-
cline induction.
We further examined the potential of the secreted and
ectopically expressed PRL to stimulate proliferation of
breast cancer cells in a paracrine manner. T47D Tet-On
cells were co-cultured in transwell chambers with T47D/
pTRE-PRL Cl. 4 cells, or as control, T47D Tet-On cells for
three days. In the T47D Tet-On: T47D/pTRE-PRL Cl. 4
co-culture, the PRL content in the medium was 5.1 nM as
measured by ELISA. Proliferation of T47D Tet-On cells
was stimulated by approximately 2.5-fold as compared to
the T47D Tet-On:T47D Tet-On control co-culture for
which the PRL level in the medium was below detection
limit of the ELISA assay (Fig. 2c). Thus, ectopically
expressed PRL can promote growth of breast cancer cells
in a paracrine fashion.
Ectopic PRL reduces proliferation of T47D/PRL cells
To address the effect of endogenous PRL on breast cancer
cell growth, we counted T47D and T47D/PRL cells during
seven days of culture. The cells were maintained in phenol
red-free DMEM medium supplemented with either 10 %
FCS or 10 % charcoal/dextran-stripped FCS (referred as
10 % CSS). We have previously shown that under the latter
conditions recombinant PRL stimulated proliferation of
T47D cells (Rasmussen et al. 2010). Surprisingly, lower
cell numbers were evident in all T47D/PRL clones as
compared with the two control T47D cell lines (Fig. 3a, b).
A similar result was obtained when cell proliferation was
measured by 3H-Thymidine incorporation (Fig. 3c, d).
In order to analyse the antiproliferative effect of ectopi-
cally expressed PRL, we investigated whether PRL affected
specific cell cycle phases. The G0/G1 fraction was increased
in T47D/PRL clones as compared to the control T47D cells
(Fig. 3e), indicating that ectopic expression of PRL causes
G0/G1 cell cycle arrest. In line, expression of Cyclin D1
protein, a critical regulator of G1 passage, was decreased in
the T47D/PRL clones as compared to the control T47D cell
lines (Fig. 3f). No significant changes in the expression level
of the anti-apoptotic protein Bcl-2 was observed in T47D/
PRL cells as compared to the control T47D cells, indicating
that T47D/PRL cells were not more prone to the apoptosis
pathway that is controlled by Bcl-2. Taken together, our data
suggest that ectopic expression of PRL may inhibit Cyclin
D1 expression, cell cycle progression, DNA replication and
hence the division of T47D breast cancer cells.
Ectopic PRL down-regulates PRLR expression
and signalling capacity
To further characterise the T47D/PRL clones we examined
the PRLR expression level (Fig. 4a). Flow cytometry
analysis revealed a reduced PRLR level on the cell surface
of T47D/PRL cells as compared to the control T47D cells.
In line, we also found a lower total PRLR protein level in
PRL-producing cells as compared to the control T47D cells
using Western blot analysis.
We further investigated the signalling response of
T47D/PRL cells to the exogenous recombinant PRL
(rPRL). The ERK1/2 pathway was proposed to play a key
role in PRL-induced T47D proliferation [27]. As expected,
rPRL activated the ERK1/2 signalling pathways in the
control T47D cells. Meanwhile, no/weak ERK1/2 stimu-
lation was observed in T47D/PRL cells (Fig. 4b).
We previously demonstrated that rPRL and estrogen
synergistically stimulated cell proliferation [6]. Here, we
tested whether ectopic PRL similarly co-stimulates estro-
gen-induced T47D/PRL proliferation. No differences in
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oestrogen-induced proliferation was observed between
transfected and wild type cells suggesting that ectopically
expressed PRL does not enhance the mitogenic effect of
oestrogen. In addition, exogenous rPRL did not further
promote proliferation of the oestrogen-stimulated T47D/
PRL cells (Fig. 4c). Together, these results indicate that the
T47D/PRL cells being constantly exposed to PRL down-
regulated the PRLR expression and its signalling capacity,
which may at least in part explain the lack of a proliferative
response to endogenous and exogenous PRL.
Discussion
A number of studies have shown that PRL and its receptor
are co-expressed in breast cancer tissue and cell lines and
thus PRL has been suggested to promote growth of the
carcinomas in an autocrine/paracrine fashion [10, 14].
Immunostaining (immunohistochemistry (IHC) or Western
blotting) was used to detect the PRL protein expression in
several studies [13, 28]. However, detection of the PRL
protein in tissues and cultured cells can be confounded by
the fact that cells can sequester PRL from serum or culture
medium. Foetal bovine serum present in cell culture
medium contains bovine PRL, which shares 75/85 %
identity/similarity to human PRL, thus human and bovine
PRL would be indistinguishable by common immunoas-
says. PRL has been detected in the epithelial cells of the
lactating mammary gland and in milk. Sequestration of
PRL from the circulation was demonstrated in vivo by
tracing radiolabelled PRL from blood to milk and in vitro
by following the transit of intact PRL through breast
A
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Fig. 3 Ectopically expressed PRL reduces proliferation of T47D
cells a, b Growth of T47D/PRL clones. Cells were seeded with a
density of 4.8 9 104 cells/well in a 24-well multi-dish in 10 % FCS
medium (a) or 10 % CSS medium (b). Cell numbers were determined
at the indicated days of culture. Mean ± SD of three independent
wells are shown; c, d Proliferation of T47D/PRL clones. Cells were
plated with a density of 1.2 9 104 cells/well in a 96-well multi-dish in
10 % FCS medium, 10 % CSS medium or serum-free DMEM
medium. Cell proliferation was estimated after three days of culture
by measuring DNA synthesis using 3H-thymidine incorporation.
Mean ± SD of six independent wells are shown; statistics is shown:
***p \ 0.001; **p \ 0.05; *p \ 0.01; ns, p [ 0.01 (t test). e Cell
cycle analysis of T47D/PRL clones. Cells (6 9 105) were plated in a
6-well multi-dish in 10 % FCS medium and cultured for three days.
DNA of cells was stained with propidum iodide, analysed by flow
cytometry and quantified using ModFit. Debris and doublets were
excluded by FSC/SSC gating. G0/G1 and G2-M populations are
illustrated in red; the dashed grey field is the S phase. The DNA
content is shown in percent ± SD of three independent wells;
f Cyclin D1 and Bcl-2 protein expression in T47D/PRL clones. Cells
were cultured for five days in 10 % FCS medium till *80 %
confluence. 20 lg of cellular protein were analysed by Western
blotting using Cyclin D1 and Bcl-2 specific antibodies. b-actin was
used as a protein loading control. The signals of Cyclin D1 and Bcl-2
were quantified and normalised by the b-actin signals. The numbers
represent percentage of the respective control T47D cell line values.
A representative of three independent experiments is shown
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epithelial cells [11]. Similar data have been reported for
placental trophoblast [29] suggesting that uptake of PRL is
a wide-spread phenomenon. Thus, the conclusion that the
PRL protein is locally synthesised in tissues cannot be
drawn based on the IHC staining and Western blotting. To
the best of our knowledge, production of PRL by cancer
cells has been directly demonstrated only in a single study
by Ginsburg and Vonderhaar [16]: de novo PRL synthesis
in the MCF7 and the oestrogen receptor-negative variant of
T47D (T47Dco) breast cancer cell lines has been demon-
strated by inhibiting the effects of PRL from cell culture
supernatants by anti-PRL antibodies. In contrary, more
recent studies did not show any growth-inhibitory effect of
PRL antagonists under standard growth conditions using
T47Dco cells [30] or MCF-7, T47D, MDA-MB-453,
MDA-MB-468 and SK-BR3 cells [31].
Expression of PRL mRNA in invasive human breast
carcinomas and breast cancer cell lines has been demon-
strated using either ISH with biotinylated primers [14, 17]
or RT-PCR followed by Southern blotting [13–15, 18],
which led to a conclusion that significant PRL expression is
common in human breast carcinomas.
In the present study, a qPCR analysis with validated
primers from Applied Biosystems was performed on a
selection of breast cancer cell lines, as well as on com-
mercially available cDNA arrays covering 144 breast
cancer biopsies. Our analysis showed that the majority of
the cell lines and biopsy samples had very low to negligible
A B
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Fig. 4 Ectopically expressed PRL down-regulates PRLR expression
and responsiveness to exogenous rPRL stimulation a PRLR protein
expression in T47D/PRL cells. Cells were harvested at 70–80 %
confluence and 40 lg protein extracts were analysed by Western
blotting using an anti-human PRLR antibody. b-actin was used as
protein loading control. The signals of PRLR were quantified and
normalised by the b-actin signals. The numbers represent a percent-
age of the respective control T47D cell line. Expression of PRLR on
the surface of the cells was analysed by flow cytometry (FACS). Cells
were stained with an anti-human PRLR mAb followed by anti-mouse
IgG-APC. The median fluorescent intensities (MFI) are shown. b Cell
signalling induced by rPRL. Cells were grown to 70–80 % confluence
in 10 % FCS medium and starved in serum-free DMEM medium for
24 h prior to treatment with 20 nM rPRL for 30 min. 20 lg of protein
extracts were analysed for activation of the ERK1/2 pathway by
Western blotting using an anti-pERK1/2 antibody. Membranes were
stripped and sequentially re-probed with antibodies detecting total
ERK1/2 protein and b-actin as loading controls. c Proliferation of
T47D/PRL cells upon E2 and PRL exposure. Cells were seeded with a
density of 1.2 9 104 cells/well in 96-well multi-dishes in 10 % CSS
medium. Next day, medium was renewed and cells were cultured for
three days in absence or presence of 1 nM 17b-estradiol (E2) and 20
nM rPRL as indicated. Cell proliferation was estimated by measuring
DNA synthesis using 3H-thymidine incorporation and stated in
percent of 10 % CSS control for each cell line. Mean ± SD of six
independent wells are shown for a representative of three independent
experiments. Statistics is shown: ***p \ 0.001; **p \ 0.05;
*p \ 0.01; ns, p [ 0.01 (t test)
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levels of PRL mRNA. Only one biopsy cDNA sample had
a relatively high PRL level, similar to that found in pla-
centa and eight samples showed low PRL mRNA levels
(8–32-fold lower than placenta).
Further, an ISH procedure was developed to analyse
PRL mRNA expression at the cellular level in clinical
samples of breast cancers. The method was validated in
several ways: 1) hybridization to T47D/PRL clones dem-
onstrated the ability of the technique to detect exogenously
expressed PRL mRNA; 2) positive control tissues (pituitary
gland and placenta) were included to demonstrate detection
of endogenous levels of PRL mRNA expression; 3) two
non-overlapping cRNA probes were shown to give iden-
tical hybridization signal on positive control tissues dem-
onstrating specific detection of the PRL transcripts; 4)
complementary sense probes did not give any hybridization
signals, again demonstrating specific hybridization using
the current method; 5) a PLAU-1 probe was used as a
positive control to demonstrate that the clinical breast
cancer samples included in the present study were suitable
for use in the ISH application. Using this well-validated
ISH procedure we were unable to demonstrate detectable
PRL mRNA expression in neither clinical breast cancers
nor in a small panel of human breast cancer cell lines. This
result supports the data generated by qPCR and strongly
suggests that PRL mRNA expression is not induced in a
minor subset of human breast cancer cells within the same
tumour, which might have been missed using the qPCR
technique. In contrast, Clevenger and co-workers have
previously reported that PRL was highly expressed in
human breast tumours using an alternative ISH protocol
[14, 17]. They applied non-complementary sense and
antisense oligonucleotide probes that were originally
designed for use as PCR primers. Unfortunately, validation
of these probes in the ISH application was not described in
any of the two papers.
It is noteworthy that our data on the lack of up-regula-
tion of PRL mRNA expression in the majority of the
analysed breast cancer samples are in a full agreement with
the data available from expression databases, including
Oncomine (an example is given in Supplementary Fig. 3S).
While we found a low/very low level of PRL mRNA
expression in few breast cancer cell lines including T47D
cells when maintained under standard growth conditions by
the qPCR analysis, the PRL protein secretion by these cells
was below detection limit of ELISA or an Nb2 assay. Sig-
nificant correlation was also not observed between the PRL
mRNA expression and immunohistochemical localisation
of the PRL protein in the previous study by Bhatavdekar
et al. [13], indicating that the presence of PRL mRNA does
not necessarily point to the presence of the PRL protein.
The T47D cell line is commonly used to study effects of
PRL in vitro due to the high PRLR expression level and a
significant ligand-induced signalling response. To investi-
gate the putative mechanism of an autocrine/paracrine
loop, we used T47D cells transfected with PRL as a model.
Interestingly, while exogenous rPRL stimulated T47D
growth [6], proliferation was reduced upon ectopic PRL
expression. Cyclin D1 expression, DNA synthesis and cell
division were decreased in three different T47D/PRL
clones as compared to the control T47D cells. The decrease
in the proliferation rate could potentially be caused by
several factors, including apoptosis, cell senescence,
endoplasmic reticulum stress upon ectopic expression of
PRL and downregulation of the PRLR expression. The
anti-apoptotic protein Bcl-2 was previously suggested to be
involved in PRL-mediated cell survival [32]. We observed
no significant changes in Bcl-2 protein expression in T47D/
PRL versus control T47D cells indicating that endogenous
PRL may not influence the apoptotic pathway that is
inhibited by Bcl-2. Despite a high level of senescence-
associated b-galactosidase activity observed in PRL-pro-
ducing clones (data not shown), it does not seem likely that
T47D/PRL cells had turned into senescence, as they were
still responsive to oestrogen. In addition, we were not able
to confirm a senescence phenotype, which is characterised
by the expression of several markers, including pATM,
cH2AX, p21 or p16-INK4a (data not shown). The reduced
growth of PRL-expressing cells also does not seem to be
due to the endoplasmic reticulum stress upon synthesis and
folding of PRL since grp78/BiP, a major sensor of endo-
plasmic reticulum stress, was not up-regulated in T47D/
PRL cells (data not shown).
A number of studies have shown a correlation between
decreased PRLR level and reduced cell proliferation. Oakes
et al. [7] have demonstrated reduced cell proliferation of
pre-invasive lesions and hence delayed tumour formation in
PRLR knock-out mice. A decreased number of T47D cells
were found upon ectopic expression of the PRLR short
splice isoform that presumably acted as a signalling-
incompetent decoy receptor [33]. Down-regulation of the
PRLR expression by shRNA reduced the growth, inva-
siveness and tumourigenicity of T47D cells [34]. Further-
more, stabilized PRLR was shown to contribute to
accelerated proliferation and invasive growth of normal
breast epithelial cells [34]. In the present study, we found a
reduced PRLR protein level in PRL-producing cells, which
at least in part could explain the observed reduction in the
cell proliferation rate. Besides PRL-induced receptor sig-
nalling, functional effects of ligand-independent PRLR
dimerization were reported [35]. Moreover, it was recently
demonstrated that growth hormone (GH) induces PRLR-
mediated rather than GH receptor-mediated signalling in
T47D breast cancer cells [36]. Thus, the molecular mecha-
nism of the tumour growth promoting effect of PRLR seems
to be quite complex and still remains to be elucidated.
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In contrast to our findings in T47D cells, increased
PRLR level and cell proliferation rate were reported in
MDA-MB-435 cells with constitutive ectopic expression of
PRL [22] and in MCF7 cells with a tetracycline-inducible
PRL expression [21]. The discrepancy between these
results and our findings may be due to differences in the
basal PRLR level. Unlike MCF7 and MDA-MB-435, T47D
cells express PRLR at a relative high level. It was descri-
bed for other growth factor receptors that a high number of
cell surface receptors caused cell differentiation upon
ligand-mediated activation, while a lower number resulted
in a proliferative response [37, 38]. The duration of the
exposure of cells to PRL may influence the expression
level and signalling capacity of PRLR. We were able to
stimulate proliferation of T47D cells by treatment with the
recombinant PRL for 3–5 days [6]. The inducible expres-
sion of PRL in MCF7 cells described by Gutzman et al.
[21] resembles such a set-up with a relatively short expo-
sure of the cells to PRL. In contrast, our transfected T47D
cells expressed PRL constitutively, which might have
contributed to the lack of responsiveness to PRL (‘toler-
ance phenotype’).
Moreover, a clear difference in the expression level and
activity of transcription factors has been demonstrated
among diverse breast cancer cell lines [39]. In MCF7 cells,
PRL induced a profound activation of AP-1, while acti-
vation of the GAS element was minor. In contrast, PRL did
not stimulate AP-1 activity in T47D cells, while a profound
activation of GAS was evident.
Since exogenous PRL was shown to promote growth of
breast tumours and breast cancer cell lines, the endoge-
nously expressed PRL was proposed to exert similar
effects. Interestingly, exogenous and autocrine hormones
may indeed act differently. A clear discrepancy in gene
regulation was evident in case of autocrine and exoge-
nously applied GH [40]. Microarray analysis of 19,000
genes identified only 167 genes commonly regulated by
exogenous and endogenous GH in human breast cancer
cells. Changes in the expression level of 305 genes in
response to endogenous vs. exogenous GH were remark-
ably different. As compared to the endogenous GH, the
exogenous GH preferentially up-regulated the expression
of genes, which are grouped within the Gene Ontology
categories of Cell Cycle, Signal Transduction, Metabolism,
Transport and Development. A similar thorough study
comparing effects of exogenous versus endogenous PRL
on gene expression has not yet been performed. So far,
only one study by Gutzman et al. [21] reported differential
effects of the exogenous and endogenous PRL on the
regulation of the PRLR and oestrogen receptor protein
expression. Our data are in agreement with the recently
published work by Ferraris et al. [41], showing that auto-
crine PRL may mediate anti-proliferative effects in mouse
anterior pituitary. In conclusion, we show that (1) PRL is
expressed at very low levels in breast tumours and (2)
ectopic PRL expression inhibits T47D breast cancer cell
proliferation. Even though our findings from in vitro
mechanistic studies cannot be extrapolated to a complex
tumour growth regulation in clinical cancers, the clinical
data presented here indicate that autocrine PRL signalling
is not a general mechanism promoting breast cancer cell
growth.
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